BehaVR Inc.
Year founded: 2016
Number of employees: 28
Founder: Aaron Gani, CEO
Amount of capital raised: $12 million
Notable investors: Confluent Health, Sumitomo-Dainippon Pharma (DSP), Chrysalis Ventures, Thornton Capital, KSTC, Future Labs Capital, Poplar Ventures, Senator William H. Frist, MD
Explain what your company does: BehaVR translates proven science into immersive and engaging therapeutic XR experiences for mental and behavioral health.
What are some major milestones in the company’s history?
- 2018 – First commercial collaboration with Confluent Health
- 2019 – Partnered with Hoag Memorial Presbyterian to create NurtureVR for maternal mental health
- 2020 – Partnered with Sumitomo-Dainippon Pharma (DSP) to create Transdiagnostic General Wellness VR product
- 2021 – Announced development and commercialization deal with Sumitomo-Dainippon Pharma for three new novel Prescription Digital VR Therapeutics for anxiety and depression
- 2021 – Awarded $3M FastTrack NIH/NIDA grant for developing Digital Therapeutic for opioid use disorder
What is your company working on right now?
- Product development across our collaboration deals with DSP, Confluent Health
- Commercial expansion of our pain and trans-diagnostic wellness products
What’s on the horizon for your company in 2022?
- Series B fundraise
- Securing additional pharma partnership for OUD DTx
Why grow your company from Kentucky?
Our founder, Aaron Gani, grew up in Kentucky, is a University of Louisville undergrad, and has been based here since returning with his wife to the area in 2006 to join Humana, where he enjoyed a 12-year tenure, culminating in the role of chief technology officer.
